Known targets — ChEMBL curated mechanism
SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9A
The experimentally established mechanism targets of Oxcarbazepine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN4A known ✓ | P35499 | 1/20 | 0.40 |
| ▸ | SCN5A known ✓ | Q14524 | 1/20 | 0.40 |
| ▸ | SCN9A known ✓ | Q15858 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.84 |
| ▸ | MAPT | P10636 | 3/20 | 0.84 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.84 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.84 |
| ▸ | MEN1 | O00255 | 2/20 | 0.84 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.84 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.84 |
| ▸ | BLM | P54132 | 1/20 | 0.84 |
| ▸ | NOTUM | Q6P988 | 3/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Oxcarbazepine SCHEMBL29359799 | 0.92 | KDM4E (1.00) | KDM4EMAPTALDH1A1CYP3A4MEN1 | |
| Oxcarbazepine SCHEMBL29433241 | 0.92 | KDM4E (1.00) | KDM4EMAPTALDH1A1CYP3A4MEN1 | |
| Oxcarbazepine SCHEMBL35129 | 0.92 | KDM4E (1.00) | KDM4EMAPTALDH1A1CYP3A4MEN1 | |
| Oxcarbazepine SCHEMBL4655725 | 0.92 | KDM4E (1.00) | KDM4EMAPTALDH1A1CYP3A4MEN1 | |
| Oxcarbazepine SCHEMBL27944289 | 0.90 | KDM4E (0.97) | KDM4EMAPTALDH1A1CYP3A4MEN1 | |
| Oxcarbazepine SCHEMBL17372732 | 0.90 | KDM4E (0.97) | KDM4EMAPTALDH1A1CYP3A4MEN1 | |
| Oxcarbazepine SCHEMBL29123953 | 0.89 | ALDH1A1 (0.89) | KDM4EMAPTALDH1A1CYP3A4MEN1 | |
| Oxcarbazepine SCHEMBL2885435 | 0.86 | KDM4E (0.89) | KDM4EMAPTALDH1A1CYP3A4MEN1 | |
| Oxcarbazepine SCHEMBL5652834 | 0.86 | KDM4E (0.89) | KDM4EMAPTALDH1A1CYP3A4MEN1 | |
| Oxcarbazepine SCHEMBL321371 | 0.84 | KDM4E (0.84) | KDM4EMAPTALDH1A1CYP3A4MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3362071-A1 | CRYSTALLIZATION METHOD AND BIOAVAILABILITY | Grünenthal GmbH (DE) | 2018-08-22 | — | — | EP | disclosed |
| WO-2017049294-A1 | CRYSTALLIZATION METHOD AND BIOAVAILABILITY | THAR PHARMACEUTICALS, INC. (US) | 2017-03-23 | — | — | WO | disclosed |
| WO-2011097269-A9 | CRYSTALLIZATION METHOD AND BIOAVAILABILITY | THAR PHARMACEUTICALS, INC. (US) | 2012-12-27 | — | — | WO | disclosed |
| EP-2531200-A1 | CRYSTALLIZATION METHOD AND BIOAVAILABILITY | Thar Pharmaceuticals, Inc. (US) | 2012-12-12 | — | — | EP | disclosed |
| WO-2011097269-A1 | CRYSTALLIZATION METHOD AND BIOAVAILABILITY | THAR PHARMACEUTICALS, INC. (US) | 2011-08-11 | — | — | WO | disclosed |